Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

121. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.JAVELIN Lung (...) 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC and disease progression after treatment with a platinum-containing doublet, an Eastern Cooperative Oncology Group performance status score of 0 or 1, an estimated life expectancy of more than 12 weeks, and adequate haematological, renal, and hepatic function. Participants were randomly

2018 EvidenceUpdates

122. Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC)

Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product

2018 Health Canada - Drug and Health Product Register

123. Lung Cancer Screening

Lung Cancer Screening New 2018 ACR Appropriateness Criteria ® 1 Lung Cancer Screening American College of Radiology ACR Appropriateness Criteria ® Lung Cancer Screening Variant 1: Lung cancer screening. Patient 55 to 80 years of age and 30 or more packs per year smoking history and currently smoke or have quit within the past 15 years. Procedure Appropriateness Category Relative Radiation Level CT chest without IV contrast screening Usually Appropriate ??? CT chest with IV contrast Usually (...) Not Appropriate ??? CT chest without and with IV contrast Usually Not Appropriate ??? FDG-PET/CT skull base to mid-thigh Usually Not Appropriate ???? MRI chest without and with IV contrast Usually Not Appropriate O MRI chest without IV contrast Usually Not Appropriate O Radiography chest Usually Not Appropriate ? Variant 2: Lung cancer screening. Patient 50 years of age or older and 20 or more packs per year history of smoking and one additional risk factor (ie, radon exposure or occupational exposure

2018 American College of Radiology

124. Durvalumab (Imfinzi) - non-small cell lung cancer (NSCLC)

Durvalumab (Imfinzi) - non-small cell lung cancer (NSCLC) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/521637/2018 EMEA/H/C/004771 Imfinzi (durvalumab) An overview of Imfinzi and why it is authorised in the EU What (...) is Imfinzi and what is it used for? Imfinzi is a medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). Imfinzi is used in adult patients with advanced cancer that cannot be removed by surgery but is not getting worse after treatment with radiation and platinum-based chemotherapy (medicines to treat cancer). Imfinzi is used specifically when the tumour produces a protein known as PD-L1. Imfinzi contains the active substance durvalumab. How is Imfinzi used? Imfinzi

2018 European Medicines Agency - EPARs

125. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. (PubMed)

Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Tobacco control efforts implemented in the United States since the 1960s have led to considerable reductions in smoking and smoking-related diseases, including lung cancer.To project reductions in tobacco use and lung cancer mortality from 2015 to 2065 due to existing tobacco control efforts.Comparative modeling approach using 4 simulation models of the natural history of lung cancer (...) that explicitly relate temporal smoking patterns to lung cancer rates.U.S. population, 1964 to 2065.Adults aged 30 to 84 years.Models were developed using U.S. data on smoking (1964 to 2015) and lung cancer mortality (1969 to 2010). Each model projected lung cancer mortality by smoking status under the assumption that current decreases in smoking would continue into the future (status quo trends). Sensitivity analyses examined optimistic and pessimistic scenarios.Under the assumption of continued decreases

2018 Annals of Internal Medicine

126. Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature (PubMed)

Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%-90% of these cancers. Smoking during cancer therapy may influence on radiotherapy and chemotherapy outcome. We aimed (...) to review the knowledge in immunotherapy.A systematic review was done. We searched for documents and articles published in English language and registered in Cochrane Library, National Health Service (NHS) Centre for Reviews and Dissemination (CRD), Embase or Medline. The search terms were (A) (Lung cancer or NSCLC) with (pembrolizumab or nivolumab) with PD-L1 with (tobacco or smoking) and (B) Lung Neoplasms and Immunotherapy and (smoking cessation or patient compliance). 68 papers were detected and two

Full Text available with Trip Pro

2018 ESMO open

127. Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study

Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study There is currently no consensus regarding the optimal postoperative follow-up strategy for patients with completely resected non-small cell lung cancer (NSCLC). We aimed to develop web-based nomograms to precisely predict site-specific postoperative recurrence in patients with NSCLC (...) and to guide individual surveillance strategies including when to follow up and what diagnostic tests to perform.We investigated the pattern of recurrence in a series of 2,017 patients with NSCLC (squamous cell carcinoma and nonlepidic invasive adenocarcinoma) who underwent complete surgical resection at Fudan University Shanghai Cancer Center (development cohort), and developed web-based clinicopathologic prediction models for conditional risk of site-specific recurrence based on Cox regression

2018 EvidenceUpdates

128. ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer

ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer Special Article Palliative thoracic radiation therapy for non- small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline Benjamin Moeller MD, PhD a, ? , Ehsan H. Balagamwala MD b , Aileen Chen MD c , Kimberly M. Creach MD d , Giuseppe Giaccone MD, PhD e , Matthew Koshy MD f , Sandra Zaky MD, MS g , George Rodrigues MD, PhD, FASTRO h a Department of Radiation (...) Oncology Center, Turlock, California h Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada Received 6 February 2018; accepted 19 February 2018 Abstract Purpose: To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lung cancer. Methods

2018 American Society for Radiation Oncology

129. Gefitinib Mylan - non-small cell lung cancer

Gefitinib Mylan - non-small cell lung cancer Gefitinib Mylan | European Medicines Agency Search Search Menu Gefitinib Mylan gefitinib Table of contents Authorised This medicine is authorised for use in the European Union. Overview Gefitinib Mylan is a cancer medicine used to treat adults who have non-small cell lung cancer that is locally advanced or metastatic (when cancer cells have spread from the original site to other parts of the body). It is used in patients whose cancer cells have (...) on the surface of cancer cells, such as EGFR on the surface of non-small cell lung cancer cells. EGFR is involved in the growth and spread of cancer cells. By blocking EGFR, Gefitinib Mylan helps to slow down the growth and spread of the cancer. Gefitinib Mylan works only in non-small cell lung cancer cells that have a mutation in their EGFR. How has Gefitinib Mylan been studied? Studies on the benefits and risks of the in the authorised use have already been carried out with the reference medicine, Iressa

2018 European Medicines Agency - EPARs

130. Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities (PubMed)

Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities Because of the profound financial crisis that commenced in Greece in 2010, severe cuts in health care spending and other restriction measures led to significant delays in the reimbursement of novel antineoplastic agents. In 2011, the Hellenic Society of Medical Oncology initiated a program of early access to epidermal growth factor receptor (EGFR (...) ) tyrosine kinase inhibitors for the treatment of patients with advanced, EGFR-mutant non-small-cell lung cancer (NSCLC). We evaluated treatment patterns and clinical outcomes in patients with EGFR-mutant or wild-type disease treated at a large center in Greece throughout the period of financial crisis.From 2011 through 2015, 252 patients with newly diagnosed advanced NSCLC were treated at the Department of Medical Oncology of the Papageorgiou Hospital, a tertiary cancer center in northern Greece. We

Full Text available with Trip Pro

2018 Journal of global oncology

131. Study protocol of a randomized controlled trial comparing integrative body-mind-spirit intervention and cognitive behavioral therapy in fostering quality of life of patients with lung cancer and their family caregivers. (PubMed)

Study protocol of a randomized controlled trial comparing integrative body-mind-spirit intervention and cognitive behavioral therapy in fostering quality of life of patients with lung cancer and their family caregivers. Compared to cancers at other sites, lung cancer often results in greater psychosocial distress to both the patients and their caregivers, due to the poor prognosis and survival rate, as well as the heavy symptom burden. In recent years, making protocols of proposed or on-going (...) intervention with cognitive behavioral therapy for enhancing quality of life of patients with lung cancer and their family caregivers. The data collection process was still on-going at the time of manuscript submission.

2018 Journal of evidence-informed social work

133. Virtual reality‐assisted localization and three‐dimensional printing‐enhanced multidisciplinary decision to treat radiologically occult superficial endobronchial lung cancer (PubMed)

Virtual reality‐assisted localization and three‐dimensional printing‐enhanced multidisciplinary decision to treat radiologically occult superficial endobronchial lung cancer Herein, we report the unique case of a 75-year-old male patient who had undergone a left upper lobectomy for lung cancer and developed an incidental superficial endobronchial squamous cell carcinoma in the right upper lobe that was not localizable on modern cross-sectional imaging modalities. The superficial (...) multidisciplinary consultation resulted in the decision to treat the lesion using photodynamic therapy. Photodynamic therapy was successfully performed without complications. A follow-up bronchoscopy two months after treatment confirmed that the superficial endobronchial squamous cell carcinoma had been cured.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

134. Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study (PubMed)

Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study Before tyrosine kinase inhibitor (TKI) therapy can be administered in patients with advanced non-small cell lung cancer (NSCLC), EGFR mutation testing is required. However, few studies have evaluated the extent of EGFR testing in real-world practice in China.A multicenter, observational study of EGFR testing in NSCLC patients in North China (...) was the first-line treatment administered to most EGFR-positive patients (56.22%), and chemotherapy in EGFR-negative patients (84.88%). Overall survival was higher in EGFR-tested than in untested patients (27.50 vs. 19.73 months; P = 0.007).Real-world EGFR testing rates for NSCLC in North China were relatively low because of clinical and social factors, including medical insurance coverage.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

135. Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors (PubMed)

Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because of hyperprogression (...) should pay attention to the use of immune checkpoint inhibitors in lung cancer patients with pleural or pericardial metastasis.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

136. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. (PubMed)

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.In this double-blind, phase 3 trial, we randomly assigned

2018 NEJM

137. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. (PubMed)

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate atezolizumab plus (...) carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression according to Response

2018 NEJM

138. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. (PubMed)

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of brigatinib, as compared with crizotinib, in patients with advanced ALK-positive NSCLC who have not previously received an ALK inhibitor is unclear.In an open-label, phase 3 trial, we randomly assigned, in a 1:1 ratio

2018 NEJM

139. Low pre‐treatment nutritional index is significantly related to poor outcomes in small cell lung cancer (PubMed)

Low pre‐treatment nutritional index is significantly related to poor outcomes in small cell lung cancer The importance of nutritional status and chronic inflammation has been emphasized in cancer. We investigated the impact of Onodera's prognostic nutritional index (OPNI) on clinical outcomes in small cell lung cancer (SCLC) patients.Data from 220 SCLC patients treated with first-line platinum-based chemotherapy from 2006 to 2017 were retrospectively reviewed. The OPNI was calculated as 10 (...) compared to the high OPNI group.SCLC patients with an OPNI < 40 showed a low tolerance to chemotherapy and a poor prognosis. Further evaluation is needed to validate these findings.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

140. Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer (PubMed)

Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD-L1 and PD-1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD-L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling (...) /paraffinization and immunohistochemistry affects the staining level of PD-L1 in non-small cell lung cancer (NSCLC).This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28-8 antibodies.There was a significant correlation between the immunoreactivity rate of tumor tissues obtained using 22C3 and 28-8 clones. No statistical difference in immunoreactivity between archival and recent samples stained either with 22C3 or 28-8 antibodies was observed. The immunoreactivity rate achieved

Full Text available with Trip Pro

2018 Thoracic cancer